We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00427804
Recruitment Status : Completed
First Posted : January 29, 2007
Results First Posted : September 2, 2011
Last Update Posted : February 4, 2013
Emory University
Information provided by (Responsible Party):
Vin Tangpricha, Atlanta VA Medical Center

Brief Summary:
This study is a pilot study to determine whether patients with TNFα excess have decreased calcium absorption in response to calcitriol (1,25-dihydroxyvitamin D, the active form of vitamin D) compared to normal controls. This initial pilot study is being done to determine if it is feasible to conduct a study where TNFα could be blocked (e.g., by anti-TNFα therapy such as Enbrel® or Remicade®) to improve vitamin D dependant calcium absorption and thus bone health.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Crohn's Disease Drug: calcitriol Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tumor Necrosis Factor-α Induces Vitamin D Resistance in Small Intestinal Calcium Absorption
Study Start Date : January 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium Vitamin D

Arm Intervention/treatment
Experimental: Calcitriol
Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
Drug: calcitriol
0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose

Primary Outcome Measures :
  1. Intestinal Absorption of Calcium [ Time Frame: 12 Weeks ]
  2. Fractional Absorption of Calcium [ Time Frame: 7 week ]
    Fractional absorption of calcium (see citation for complete details)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males
  • Age 18 to 50
  • History of Crohn's disease or Rheumatoid Arthritis (cases) or healthy individuals (controls)

Exclusion Criteria:

  • Subjects already taking activated vitamin D medications such as calcitriol, Zemplar®, Hectoral®
  • Vitamin D deficiency defined as 25(OH)D ≤ 20 ng/ml
  • Post-menopausal women (absence of menses for greater than 6 months by history or FSH level >20)
  • History of nephrolithiasis
  • History of hypercalcemia or hypercalciuria
  • Short bowel disease
  • Glucocorticoid use
  • Use of osteoporosis medication (bisphosphonate, calcitonin or teriparatide)
  • Chronic kidney disease (calculated GFR <60 ml/min/1.73 m2)
  • History of hyperparathyroidism (PTH greater than upper limit of normal) or
  • Hypoparathyroidism (PTH below lower limit of normal)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00427804

Layout table for location information
United States, Georgia
Atlanta VAMC
Atlanta, Georgia, United States, 30030
Sponsors and Collaborators
Atlanta VA Medical Center
Emory University
Layout table for investigator information
Principal Investigator: Vin Tangpricha, M.D. Ph.D. Emory University
Publications of Results:
Layout table for additonal information
Responsible Party: Vin Tangpricha, Staff Physician, Atlanta VA Medical Center
ClinicalTrials.gov Identifier: NCT00427804    
Other Study ID Numbers: Vitamin D-2007
First Posted: January 29, 2007    Key Record Dates
Results First Posted: September 2, 2011
Last Update Posted: February 4, 2013
Last Verified: January 2013
Keywords provided by Vin Tangpricha, Atlanta VA Medical Center:
Calcium absorption
Vitamin D
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Pathologic Processes
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Bone Density Conservation Agents